Pancreatic Cancer Research

ResearcherMarche Polytechnic UniversityNo recent work listed

Kalliopi Andrikou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0572-5321; OpenAlex author ID A5081324410. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 5 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper

Papers 11

  1. Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. Co-author DOI 10.1177/0300891620976945↗
  2. First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? Co-author DOI 10.1016/j.ejca.2020.06.031↗
  3. Emerging antibodies for the treatment of pancreatic cancer. Co-author DOI 10.1080/14728214.2017.1293649↗
  4. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Co-author DOI 10.1016/j.ejso.2016.06.398↗
  5. [Treatment of pancreatic cancer. Actuality and perspective]. First author DOI 10.1701/1868.20404↗
  6. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Co-author DOI 10.18632/oncotarget.5197↗
  7. Lgr5 expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses. Co-author DOI 10.2217/fon.15.27↗
  8. KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma. Co-author DOI 10.2217/fon.15.98↗
  9. HER family receptor expression and prognosis in pancreatic cancer. Co-author DOI 10.5301/jbm.5000157↗
  10. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Co-author DOI 10.1155/2014/183852↗
  11. Cetuximab: still an option in the treatment of pancreatic cancer? First author DOI 10.1517/14712598.2013.786697↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stefano Cascinu · 10 shared papers, 2013–2021 · strength 0.57
  2. Alessandro Bittoni · 7 shared papers, 2014–2016 · strength 0.33
  3. Luca Faloppi · 4 shared papers, 2013–2021 · strength 0.24
  4. Giulia Rovesti · 2 shared papers, 2020–2021 · strength 0.19
  5. Francesco Piva · 3 shared papers, 2015 · strength 0.13
  6. Mario Scartozzi · 2 shared papers, 2015–2021 · strength 0.13
  7. Massimo Falconi · 2 shared papers, 2015–2016 · strength 0.10
  8. Andrea Pretta · 1 shared paper, 2021 · strength 0.09
  9. Eleonora Lai · 1 shared paper, 2021 · strength 0.09
  10. Giulia Orsi · 1 shared paper, 2021 · strength 0.09
  11. Caterina Vivaldi · 1 shared paper, 2020 · strength 0.09
  12. Silvia Catanese · 1 shared paper, 2020 · strength 0.09
  13. Vincenzo Formica · 1 shared paper, 2020 · strength 0.09
  14. Irene Pecora · 1 shared paper, 2020 · strength 0.09
  15. Lorenzo Fornaro · 1 shared paper, 2020 · strength 0.09
  16. Enrico Vasile · 1 shared paper, 2020 · strength 0.09
  17. Stefano Partelli · 1 shared paper, 2016 · strength 0.05
  18. Silvia Matilde Zanon · 1 shared paper, 2016 · strength 0.05
  19. Gianpaolo Balzano · 1 shared paper, 2016 · strength 0.05
  20. Michele Reni · 1 shared paper, 2016 · strength 0.05
  21. Stefano Crippa · 1 shared paper, 2016 · strength 0.05
  22. Matteo Giulietti · 1 shared paper, 2015 · strength 0.04
  23. Roberto Labianca · 1 shared paper, 2015 · strength 0.04
  24. Stefania Mosconi · 1 shared paper, 2015 · strength 0.04
  25. Sandro Barni · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.